February 19, 2025

Osteoporosis Treatment Market Dynamics: Unveiling Growth Factors

Osteoporosis Treatment Market

Osteoporosis is a skeletal disorder characterized by low bone mass and micro-architectural deterioration of bone tissue, leading to increased bone fragility and risk of fractures. It is primarily treated through medication that either builds new bone or slows down bone loss. Drugs such as bisphosphonates, selective estrogen receptor modulators (SERMs), parathyroid hormone therapies, monoclonal antibodies, and anabolic agents are widely used for osteoporosis treatment.

The global osteoporosis treatment market is growing significantly over the past few years. There is a wide range of medications available for osteoporosis treatment that help strengthen bones and reduce the risk of fractures. The bisphosphonate drug class leads the market owing to its effectiveness and wide usage. However, other newer drugs like PTH therapies, monoclonal antibody medications, and anabolic agents are gaining more traction due to targeted mechanisms of action and convenience of administration through subcutaneous injections or nasal spray.

The global Osteoporosis Treatment Market is estimated to be valued at US$ 14.01 billion in 2023 and is expected to exhibit a CAGR of 3.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
One of the major trends in the osteoporosis treatment market is the increased focus on combination therapies. Combining drugs that work via different mechanisms, such as anti-resorptive drugs with anabolic medications, allows addressing various aspects of bone loss and rebuilding bone mass more effectively. Many clinical studies are being conducted to evaluate the efficacy of drug combinations for osteoporosis. This is expected to open up new avenues for combination products in the coming years. Another notable trend is the development of pipeline drugs featuring novel mechanisms of action and more targeted approaches. A few emerging drug classes in clinical trials include sclerostin antibodies, cathepsin K inhibitors, and RANK ligand inhibitors that can potentially overcome limitations of current medications and further improve patient outcomes.

Porter’s Analysis

Threat of new entrants: The threat of new entrants in the osteoporosis treatment market is moderate as it requires high R&D investments and regulatory approvals.

Bargaining power of buyers: The bargaining power of buyers is moderate due to the availability of generic drugs.

Bargaining power of suppliers: The bargaining power of suppliers is low due to the presence of many raw material suppliers.

Threat of new substitutes: The threat of new substitutes is low as there are limited treatment options for osteoporosis currently.

Competitive rivalry: The competitive rivalry is high among the key players to gain higher market share.

Key Takeaways

The global osteoporosis treatment market is expected to witness high growth.

Regional analysis: The North America region currently dominates the market owing to increasing osteoporosis prevalence and availability of advanced treatment options. Europe and Asia Pacific regions also offer lucrative opportunities due to growing aging population.

Key players operating in the osteoporosis treatment market are Teva Pharmaceutical Industries Ltd., DAIICHI SANKYO COMPANY, LIMITED, Amgen Inc., Dr. Reddy’s Laboratories Ltd., Viatris Inc., Ligand Pharmaceuticals Incorporated, Eli Lilly and Company, Asahi Kasei Corporation, F. Hoffmann-La Roche Ltd, EffRx Pharmaceuticals SA, Novartis AG, Merck & Co., Inc., GSK plc., and Pfizer Inc. Eli Lilly and Company recently received approval for its osteoporosis drug called Prolia in India.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it

Money Singh
+ posts

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. 

Money Singh

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. 

View all posts by Money Singh →